AtriCure (ATRC) COO receives stock awards and surrenders shares for taxes

Rhea-AI Filing Summary

AtriCure, Inc. Chief Operating Officer Douglas J. Seith reported equity compensation and related tax withholding in company stock. On March 1, 2026, he received 42,386 shares of common stock as a restricted stock award that vests in three equal annual installments. He also acquired 25,532 shares through the vesting and release of a performance share award after company performance goals and service requirements were met. To cover tax obligations from these vestings, he transferred 22,948 shares back to the company at $31.26 per share. Following these transactions, he directly owned 229,340 shares of AtriCure common stock.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Seith Douglas J

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	42,386	$0.00	--
Grant/Award	Common Stock	25,532	$0.00	--
Tax Withholding	Common Stock	22,948	$31.26	$717K

Holdings After Transaction: Common Stock — 226,756 shares (Direct)

Footnotes (1)

1. The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. One third of the shares will vest annually upon the respective one, two, and three year anniversaries of the date of grant. The Reporting Person acquired these shares pursuant to the vesting and release of a Performance Share Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The award had Company performance goals and a service period requirement which were met. The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award or Performance Share Award.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Seith Douglas J

(Last) (First) (Middle)

7555 INNOVATION WAY

(Street)

MASON OH 45040-9695

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AtriCure, Inc. [ ATRC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/01/2026		A		42,386	A	$0(1)	226,756	D
Common Stock	03/01/2026		A		25,532	A	$0(2)	252,288	D
Common Stock	03/01/2026		F		22,948(3)	D	$31.26	229,340	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. One third of the shares will vest annually upon the respective one, two, and three year anniversaries of the date of grant.

2. The Reporting Person acquired these shares pursuant to the vesting and release of a Performance Share Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The award had Company performance goals and a service period requirement which were met.

3. The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award or Performance Share Award.

Remarks:

	/s/ Douglas J. Seith	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did AtriCure (ATRC) disclose about Douglas Seith’s recent stock transactions?

AtriCure reported that COO Douglas J. Seith received restricted and performance-based stock awards and transferred shares back to the company for tax withholding. These transactions reflect equity compensation rather than open-market buying or selling of ATRC shares.

How many AtriCure (ATRC) shares were granted to COO Douglas Seith?

Douglas J. Seith received 42,386 restricted shares and 25,532 performance-based shares of AtriCure common stock. These awards were granted under the 2023 Stock Incentive Plan following vesting conditions tied to time-based service and company performance goals.

Why did Douglas Seith transfer AtriCure (ATRC) shares back to the company?

Douglas J. Seith transferred 22,948 AtriCure shares back to the company to satisfy tax withholding obligations. The taxes arose upon vesting and release of restricted and performance share awards granted under AtriCure’s 2023 Stock Incentive Plan.

What vesting terms apply to Douglas Seith’s new AtriCure restricted stock award?

The new restricted stock award to Douglas J. Seith vests in three equal annual installments. One-third of the 42,386 shares will vest on each of the first, second, and third anniversaries of the March 1, 2026 grant date, assuming continued service.

How many AtriCure (ATRC) shares does Douglas Seith own after these transactions?

After the reported grants and tax-withholding transfer, Douglas J. Seith directly owns 229,340 shares of AtriCure common stock. This figure reflects his updated beneficial ownership following the March 1, 2026 equity compensation events.

Were Douglas Seith’s AtriCure (ATRC) transactions open-market buys or sells?

The transactions were not open-market trades. They consisted of stock grants and the delivery of 22,948 shares back to AtriCure at $31.26 per share to cover tax liabilities arising from vesting of equity awards.